SNHG9 and prostate carcinoma: Their difference in activity was in line with the gene’s expression change in prostate cancer, with RPS2-SNHG9 having increased activity, fitting with RPS2 overexpression in prostate cancer94 and TMEM127-CIAO1 abolishing activity, in line with TMEM127 observed downregulation in cancer63.